Pfizer is due to release its earnings in the US tonight and the stage is set for what's been dubbed "record-shattering revenues", and analysts believe two new products will bring sales beyond the US$1 billion mark. But can the pharmaceutical giant sustain these gains in the medium to long term? Michelle Martin finds out.

LIVE WELL WITH MICHELLE: Divorce: How to Protect Your Peace
24:48

Money and Me: CPF Nomination - not as difficult as you think
23:31

Market View: Trillion-Dollar AI Momentum & Wall Street’s Record Run, SK Hynix, Samsung, Micron, Nvidia, Salesforce, Snowflake, Amazon, Eli Lilly, PDD Holdings, Temu, Lululemon, TSMC
11:55